Several ebolaviruses cause outbreaks of severe disease. Vaccines and monoclonal
antibody cocktails are available to treat Ebola virus (EBOV) infections, but not Sudan virus …

While neutralizing antibodies are highly effective against ebolavirus infections, current
experimental ebolavirus vaccines primarily elicit species-specific antibody responses. Here …

Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of
lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral …

Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS) of
ebolavirus glycoproteins have been unsuccessful, largely because the RBS is occluded on …

Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies
(mAbs) that are effective against multiple ebolaviruses are important for therapeutics …

There are five antigenically distinct ebolaviruses that cause hemorrhagic fever in humans or
non-human primates (Ebola virus, Sudan virus, Reston virus, Taï Forest virus, and …

Recent studies have suggested that antibody-mediated protection against the Ebolaviruses
may be achievable, but little is known about whether or not antibodies can confer cross …

The severity of the 2014–2016 ebolavirus outbreak in West Africa expedited clinical
development of therapeutics and vaccines though the countermeasures on hand were …

Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several
strategies have been developed in the past to treat EBOV infection, including the antibody …

Out of an estimated 31,100 cases since their discovery in 1976, ebolaviruses have caused
approximately 13,000 deaths. The vast majority (∼ 11,000) of these occurred during the …